Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 2
2007 1
2008 3
2009 1
2010 3
2011 2
2012 6
2013 3
2014 3
2015 5
2016 4
2017 2
2019 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I, Dubischar K, Lilja A, Eder-Lingelbach S, Hochreiter R, Jaramillo JC, Junker H, Krammer M, Pusic P, Querton B, Larcher-Senn J, Hoffmann M, Pöhlmann S, Finn A; Valneva Phase 3 Booster Trial Group. Taucher C, et al. Among authors: lilja a. J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3. J Infect. 2023. PMID: 37406777 Clinical Trial.
Development of a high-throughput RT-PCR based viral infectivity assay for monitoring the stability of a replicating recombinant Lymphocytic Choriomeningitis viral vector.
Gupta V, Antunez LR, Saleh-Birdjandi S, Kumru OS, Pospisil R, Lilja A, Fuhrmann G, Smith L, Volkin DB, Joshi SB. Gupta V, et al. Among authors: lilja a. J Virol Methods. 2022 Mar;301:114440. doi: 10.1016/j.jviromet.2021.114440. Epub 2021 Dec 24. J Virol Methods. 2022. PMID: 34954306 Free article.
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.
Schwendinger M, Thiry G, De Vos B, Leroux-Roels G, Bruhwyler J, Huygens A, Ganeff C, Buchinger H, Orlinger KK, Pinschewer DD, Monath TP, Lilja AE. Schwendinger M, et al. Among authors: lilja ae. J Infect Dis. 2022 Apr 19;225(8):1399-1410. doi: 10.1093/infdis/jiaa121. J Infect Dis. 2022. PMID: 32313928 Free PMC article. Clinical Trial.
Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.
Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, Chandrashekar A, Cabral JM, Lim M, Iampietro MJ, Provine NM, Bricault CA, Seaman M, Orlinger K, Aspoeck A, Fuhrmann G, Lilja AE, Monath T, Mangeat B, Pinschewer DD, Barouch DH. Penaloza MacMaster P, et al. Among authors: lilja ae. Vaccine. 2017 Jan 3;35(1):1-9. doi: 10.1016/j.vaccine.2016.11.063. Epub 2016 Nov 26. Vaccine. 2017. PMID: 27899229 Free PMC article.
Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR, Berka U, Watson E, Aistleithner M, Kiefmann B, Mangeat B, Swanson EC, Gillis PA, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, Pinschewer DD, Lilja AE, Schwendinger M, Guirakhoo F, Monath TP, Orlinger KK. Schleiss MR, et al. Among authors: lilja ae. Clin Vaccine Immunol. 2017 Jan 5;24(1):e00300-16. doi: 10.1128/CVI.00300-16. Print 2017 Jan. Clin Vaccine Immunol. 2017. PMID: 27795301 Free PMC article.
36 results